[AEONCR] QoQ Cumulative Quarter Result on 31-May-2022 [#1]

Stock
[AEONCR] AEON CREDIT SERVICE (M) BHD
Announcement Date
04-Jul-2022
Admission Sponsor
-
Sponsor
-
Financial Year
28-Feb-2023
Quarter
31-May-2022 [#1]
Profit Trend
QoQ- -55.37%
YoY- -0.01%
Quarter Report
Latest QR
Upcoming QR
AEONCR's Result
AEONCR's Financial Summary
View:
Show?
Cumulative Result
28/02/23 30/11/22 31/08/22 31/05/22 28/02/22 30/11/21 31/08/21 CAGR
Revenue 1,640,245 1,207,581 789,742 390,571 1,524,880 1,161,912 785,441 63.59%
PBT 546,976 417,165 315,582 215,535 526,820 482,031 318,003 43.69%
Tax -129,291 -94,820 -76,864 -52,466 -161,401 -139,992 -79,428 38.50%
NP 417,685 322,345 238,718 163,069 365,419 342,039 238,575 45.41%
-
NP to SH 417,685 322,345 238,718 163,069 365,419 342,039 238,575 45.41%
-
Tax Rate 23.64% 22.73% 24.36% 24.34% 30.64% 29.04% 24.98% -
Total Cost 1,222,560 885,236 551,024 227,502 1,159,461 819,873 546,866 71.22%
-
Net Worth 2,323,300 2,259,473 2,231,389 2,221,176 2,001,612 1,947,997 1,894,383 14.61%
Dividend
28/02/23 30/11/22 31/08/22 31/05/22 28/02/22 30/11/21 31/08/21 CAGR
Div 126,377 72,762 72,762 - 123,824 72,762 72,762 44.63%
Div Payout % 30.26% 22.57% 30.48% - 33.89% 21.27% 30.50% -
Equity
28/02/23 30/11/22 31/08/22 31/05/22 28/02/22 30/11/21 31/08/21 CAGR
Net Worth 2,323,300 2,259,473 2,231,389 2,221,176 2,001,612 1,947,997 1,894,383 14.61%
NOSH 255,307 255,307 255,307 255,307 255,307 255,307 255,307 0.00%
Ratio Analysis
28/02/23 30/11/22 31/08/22 31/05/22 28/02/22 30/11/21 31/08/21 CAGR
NP Margin 25.46% 26.69% 30.23% 41.75% 23.96% 29.44% 30.37% -
ROE 17.98% 14.27% 10.70% 7.34% 18.26% 17.56% 12.59% -
Per Share
28/02/23 30/11/22 31/08/22 31/05/22 28/02/22 30/11/21 31/08/21 CAGR
RPS 642.46 472.99 309.33 152.98 597.27 455.10 307.64 63.60%
EPS 159.62 124.28 91.53 63.87 139.17 132.00 91.47 45.09%
DPS 49.50 28.50 28.50 0.00 48.50 28.50 28.50 44.63%
NAPS 9.10 8.85 8.74 8.70 7.84 7.63 7.42 14.61%
Adjusted Per Share Value based on latest NOSH - 255,307
28/02/23 30/11/22 31/08/22 31/05/22 28/02/22 30/11/21 31/08/21 CAGR
RPS 321.23 236.50 154.66 76.49 298.64 227.55 153.82 63.60%
EPS 81.80 63.13 46.75 31.94 71.56 66.99 46.72 45.41%
DPS 24.75 14.25 14.25 0.00 24.25 14.25 14.25 44.63%
NAPS 4.55 4.425 4.37 4.35 3.92 3.815 3.71 14.61%
Price Multiplier on Financial Quarter End Date
28/02/23 30/11/22 31/08/22 31/05/22 28/02/22 30/11/21 31/08/21 CAGR
Date 28/02/23 30/11/22 30/08/22 31/05/22 28/02/22 30/11/21 30/08/21 -
Price 12.00 12.86 14.10 14.56 14.68 12.90 12.06 -
P/RPS 1.87 2.72 4.56 9.52 2.46 2.83 3.92 -39.03%
P/EPS 7.33 10.19 15.08 22.80 10.26 9.63 12.91 -31.50%
EY 13.63 9.82 6.63 4.39 9.75 10.39 7.75 45.85%
DY 4.13 2.22 2.02 0.00 3.30 2.21 2.36 45.36%
P/NAPS 1.32 1.45 1.61 1.67 1.87 1.69 1.63 -13.15%
Price Multiplier on Announcement Date
28/02/23 30/11/22 31/08/22 31/05/22 28/02/22 30/11/21 31/08/21 CAGR
Date 11/04/23 21/12/22 29/09/22 04/07/22 05/04/22 23/12/21 28/09/21 -
Price 11.92 12.52 13.48 13.62 15.30 13.30 11.88 -
P/RPS 1.86 2.65 4.36 8.90 2.56 2.92 3.86 -38.61%
P/EPS 7.29 9.92 14.42 21.32 10.69 9.93 12.71 -31.03%
EY 13.72 10.08 6.94 4.69 9.35 10.07 7.87 44.99%
DY 4.15 2.28 2.11 0.00 3.17 2.14 2.40 44.20%
P/NAPS 1.31 1.41 1.54 1.57 1.95 1.74 1.60 -12.51%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.

NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ ⃤ & YoY ⃤ figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment